The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update

[1]  J. Fütterer,et al.  Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. , 2015, European urology.

[2]  R. Gabe,et al.  PROMIS — Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer☆ , 2015, Contemporary clinical trials.

[3]  D. Moses,et al.  Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. , 2014, The Journal of urology.

[4]  Shyam Natarajan,et al.  Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. , 2014, European urology.

[5]  Shyam Natarajan,et al.  The role of magnetic resonance imaging in delineating clinically significant prostate cancer. , 2014, Urology.

[6]  Jurgen J Fütterer,et al.  Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. , 2014, AJR. American journal of roentgenology.

[7]  H. Ahmed,et al.  The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level—Can it rule out clinically significant prostate cancer? , 2014, Urologic oncology.

[8]  P. Choyke,et al.  Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. , 2013, The Journal of urology.

[9]  M Emberton,et al.  Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard , 2013, Prostate Cancer and Prostatic Disease.

[10]  Jan van der Meulen,et al.  Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. , 2013, Radiology.

[11]  P. P. Iu,et al.  ESUR prostate MR guidelines. , 2013, European radiology.

[12]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[13]  T. Sone,et al.  Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. , 2011, AJR. American journal of roentgenology.

[14]  H. Ahmed,et al.  Multi-Parametric Magnetic Resonance Imaging to Rule-In and Rule-Out Clinically Important Prostate Cancer in Men at Risk: A Cohort Study , 2011, Urologia Internationalis.

[15]  Josep Comet,et al.  Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer. , 2011, AJR. American journal of roentgenology.

[16]  Clare Allen,et al.  Is it time to consider a role for MRI before prostate biopsy? , 2009, Nature Reviews Clinical Oncology.

[17]  Clare Allen,et al.  How good is MRI at detecting and characterising cancer within the prostate? , 2006, European urology.

[18]  James G Wright,et al.  Levels of evidence [1] , 2006 .

[19]  Yipeng Hu,et al.  The PICTURE study -- prostate imaging (multi-parametric MRI and Prostate HistoScanning™) compared to transperineal ultrasound guided biopsy for significant prostate cancer risk evaluation. , 2014, Contemporary clinical trials.

[20]  T. Mitani,et al.  Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging? , 2011, Diagnostic and interventional radiology.